人绒毛膜促性腺激素治疗与艾滋病相关的卡波西肉瘤。

Human chorionic gonadotropin in the treatment of HIV-related Kaposi's sarcoma.

作者信息

Tavio M, Nasti G, Simonelli C, Vaccher E, De Paoli P, Giacca M, Tirelli U

机构信息

Division of Medical Oncology and AIDS, Centro di Riferimento Oncologico, Trieste, Italy.

出版信息

Eur J Cancer. 1998 Sep;34(10):1634-7. doi: 10.1016/s0959-8049(98)00154-3.

DOI:10.1016/s0959-8049(98)00154-3

PMID:9893642

Abstract

To evaluate the antineoplastic activity of human chorionic gonadotropin (hCG) in the treatment of HIV-related Kaposi's sarcoma (KS), two clinical trials focusing on two different schedules of administration and types of hCG preparation were conducted. In the low-dose group, hCG (Profasi-HP) was administered three times a week intramuscularly at a dose ranging from 4000 to 32,000 IU for 4 months and no objective response was observed among 5 evaluable patients. In the high-dose group, hCG (Gonadotrafon) was given intramuscularly three times a week at a dose ranging from 100,000 to 300,000 IU for 3 months with 1 partial response among 8 evaluable patients. In 6 patients evaluated for HIV viral load, no significant reduction in HIV viraemia was observed. In conclusion, hCG showed very limited activity against KS and no influence on HIV viral load, along with emerging dose-limiting toxicity and high cost of the therapy.

摘要

为评估人绒毛膜促性腺激素（hCG）治疗人类免疫缺陷病毒（HIV）相关卡波西肉瘤（KS）的抗肿瘤活性，开展了两项针对不同给药方案和hCG制剂类型的临床试验。在低剂量组中，hCG（普丽康 - HP）每周肌肉注射3次，剂量为4000至32000国际单位，持续4个月，5例可评估患者中未观察到客观缓解。在高剂量组中，hCG（戈那瑞林）每周肌肉注射3次，剂量为100000至300000国际单位，持续3个月，8例可评估患者中有1例部分缓解。在6例评估HIV病毒载量的患者中，未观察到HIV病毒血症有显著降低。总之，hCG对KS的活性非常有限，对HIV病毒载量无影响，同时出现了剂量限制性毒性和高昂的治疗成本。